obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm; and a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ± 0.2 ppm.

9. The salt of any one of claims 1-3 and 5-8, wherein the salt is a polymorph of maleate polymorph Form B, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2 obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

10. A pharmaceutical composition comprising the salt of any of claims 1-3 and 4-9.

11. Use of a therapeutically effective amount of the pharmaceutical composition of claim ~~11~~ for the manufacture of a medicament for the treatment of cancer.

12. Use of a salt of any one of claims 1-9 in the manufacture of a medicament for the treatment of cancer.

obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three ^{13}C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm; and a solid state NMR spectrum comprising a ^{19}F chemical shift at -123.1 ± 0.2 ppm.

9. The salt of any one of claims 1-3 and 5-8, wherein the salt is a polymorph of maleate polymorph Form B, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2 obtained using copper K-alpha$_1$ X-rays at a wavelength of 1.5406 Ångstroms.

10. A pharmaceutical composition comprising the salt of any of claims 1-3 and 4-9.

11. Use of a therapeutically effective amount of the pharmaceutical composition of claim 10 for the manufacture of a medicament for the treatment of cancer.

12. Use of a salt of any one of claims 1-9 in the manufacture of a medicament for the treatment of cancer.